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BACkgrOunD: Human cytomegalovirus is an important cause of 
morbidity and mortality in immunocompromised patients. Qualitative 
polymerase chain reaction (PCR) has proven to be a sensitive and 
effective technique in defining active cytomegalovirus infection, in 
addition to having low cost and being a useful test for situations in 
which there is no need for quantification. Real-time PCR has the 
advantage of quantification; however, the high cost of this methodol-
ogy makes it impractical for routine use. 
OBJECTIVE: To apply a nested PCR assay to serum (sPCR) and to 
evaluate its efficiency to diagnose active cytomegalovirus infection 
compared with PCR of peripheral blood leukocytes (L-PCR).
METhODS: Samples of 37 patients were prospectively evaluated. An 
internal control was created and applied to sPCR to exclude false-
negative results.
rESulTS: In total, 21 patients (57%) developed active cytomegalo-
virus infection. After analyzing the two methods for the diagnosis of 
active infection, higher sensitivity and negative predictive value of the 
L-PCR versus sPCR (100% versus 62%), and higher specificity and 
positive predictive value of sPCR versus L-PCR (81% versus 50% and 
72%, respectively) were observed. Discordant results were observed in 
11 patients who were L-PCR-positive but sPCR-negative for active 
cytomegalovirus infection, five of whom developed clinical symptoms 
of cytomegalovirus. Clinical symptoms were observed in 14 patients, 
12 of whom were diagnosed with active infection by nested L-PCR 
(P=0.007) and seven by nested sPCR (P=0.02). Higher specificity and 
a positive predictive value for sPCR were observed. 
COnCluSIOn: Nested L-PCR and sPCR were considered to be 
complementary methods for the diagnosis and management of symp-
tomatic cytomegalovirus infection.
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la réaction en chaîne de la polymérase sur 
leucocytes du sang périphérique et sur sérum sont 
des méthodes complémentaires pour surveiller une 
infection active à cytomégalovirus chez des patients 
greffés
hISTOrIQuE : Le cytomégalovirus humain est une cause importante 
de morbidité et de mortalité chez les patients immunodéprimés. Il est 
démontré que la réaction en chaîne de la polymérase (PCR) qualitative 
est une technique sensible et efficace pour définir l’infection active à 
cytomégalovirus, sans compter qu’elle est peu coûteuse et qu’elle est 
pratique dans les situations où la quantification est inutile. La PCR en 
temps réel a l’avantage d’inclure la quantification, mais en raison de son 
coût élevé, il est impossible d’y recourir systématiquement.
OBJECTIF : Appliquer la PCR sur sérum (PCRs) et en évaluer 
l’efficacité pour diagnostiquer une infection active à cytomégalovirus 
par rapport à la PCR sur leucocytes du sang périphérique (PCR-L).
MÉThODOlOgIE : Les chercheurs ont effectué une évaluation 
prospective de 37 patients. Ils ont créé un contrôle interne et l’ont 
appliqué au PCRs en vue d’exclure les résultats faux négatifs.
rÉSulTATS : Au total, 21 patients (57 %) ont développé une 
infection active à cytomégalovirus. Après l’analyse des deux méthodes 
diagnostiques de l’infection active, les chercheurs ont remarqué la plus 
forte sensibilité et la valeur prédictive négative de la PCR-L par 
rapport à la PCRs (100 % par rapport à 62 %) et la plus forte spécificité 
et la valeur prédictive positive de la PCRs par rapport à la PCR-L 
(81 % par rapport à 50 % et 72 %, respectivement). Ils ont constaté 
des résultats discordants chez 11 patients dont la PCR-L était positive, 
mais la PCRs était négative à l’infection active à cytomégalovirus, 
dont cinq ont manifesté des symptômes cliniques. Les chercheurs ont 
remarqué des symptômes cliniques chez 14 patients; dans 12 cas, 
l’infection active a été diagnostiquée par PCR-L (P=0,007) et dans 
sept, par PCRs (P=0,02). Ils ont également observé que la PCRs avait 
une plus forte spécificité et une valeur prédictive positive.
COnCluSIOn : La PCR-L et la PCRs étaient considérées comme 
des méthodes complémentaires pour diagnostiquer et prendre en 
charge l’infection à cytomégalovirus symptomatique.
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Human cytomegalovirus (CMV) is an important cause of morbid-ity and mortality in immunocompromised patients, such as trans-
plant recipients (1-3). Early diagnosis of disease in these patients is 
essential to initiate antiviral therapy, thus enabling prompt and appro-
priate treatment. Therefore, the availability of a sensitive test, capable 
of detecting active CMV infection, is crucial.
The limited resources available for public health care lead to the 
need for important considerations regarding simplicity and cost of 
diagnostic assays (4). Qualitative polymerase chain reaction (PCR) 
has proven to be a sensitive and effective technique in defining active 
CMV infection, and is especially useful in situations in which there is 
no need for quantification in addition to having a low cost (5). Real-
time PCR has the advantage of quantification; however, the high cost of 
this methodology makes it impractical for routine use (6).
Peripheral blood leukocytes (PBL) PCR and serum/plasma PCR 
(L-PCR and sPCR, respectively) are assays largely used in the diagno-
sis of active CMV infection. Some reports suggest that leukocyte-
based tests are superior for detecting CMV DNA (7,8); however, due 
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to its high sensitivity, detection of CMV DNA in peripheral leuko-
cytes using PCR does not always correlate with the development of 
CMV disease. Other studies have shown that plasma/serum positivity 
is more correlated with active infection, in addition to presenting 
easier processing (9,10).
Serological analysis methodologies are considered to be useful for 
the verification of a history of exposure of the patient to human CMV 
(11). The determination of active human CMV infection in trans-
plant patients through serological methods has limitations due to the 
intense immunosuppression to which patients are subjected (12). 
Studies confirm disability and absence of antibodies in immunosup-
pressed patients with symptomatic and disseminated disease (13). 
Therefore, serological analyses were not applied in the present study for 
the diagnosis of active human CMV infection in the post-transplant 
period.
The aim of the present study was to develop and apply a nested 
PCR assay for serum (sPCR) and to evaluate its efficiency to diagnose 
active CMV infection, compared with L-PCR – the PCR-based avail-
able method. Thus, statistical parameters of the test, such as sensitiv-
ity, specificity and positive and negative predictive values, were 
calculated, as well as the synthesis of an internal control, which was 
used in sPCR, enabling major test reliability for eliminating the pres-
ence of possible inhibitors and the exclusion of false-negative results. 
METhODS
Patients and samples
A total of 37 patients were monitored in the present study – 20 under-
went kidney transplant and 17 hematopoietic stem cell transplant. 
Peripheral blood and serum specimens were drawn weekly during the 
first month after renal transplant and, after this period, every two 
weeks until completing four months; only serum was collected from 
those who were submitted to hematopoietic stem cell transplant until 
bone marrow engraftment (leukocyte count >0.5×109/L for two or 
more consecutive days and platelet count >20×109/L for five consecu-
tive days). After observing these criteria, the peripheral blood and 
serum collection continued every two weeks until the fifth month after 
transplant, resulting in a total of 400 peripheral blood samples – an 
average of 10 specimens collected per patient.
Approximately 4.0 mL of EDTA-anticoagulated whole blood was 
collected from each patient and used for extraction of nucleic acid 
from PBLs, as described below. Sera were collected in appropriate 
tube(s) and, after 30 min, were centrifuged and stored at –20°C until 
processed. Thus, the presence of viral particles in serum was avoided 
due to cell lysis because of delayed sample processing.
Clinical information was collected from medical records and pro-
spectively analyzed. Active CMV infection, CMV recurrence and 
CMV disease were defined according to the recommendations pub-
lished by Ljungman et al (14). Active CMV infection was defined by 
observing two consecutive L-PCR and/or sPCR results within an 
interval ≤30 days (15,16). CMV-related diseases were defined as signs 
or symptoms of these disorders in association with a confirmation of 
CMV infection by laboratory tests. CMV disease was defined by 
immunohistochemical analysis of biopsy specimens as well as clinical 
signs and symptoms, such as unexplained fever (>38°C), leukopenia 
(white blood cell count <3.5×109/L) and/or thrombocytopenia (platelet 
count <100×109/L), gastrointestinal symptoms, arthralgia, hepatitis, 
enteritis, retinitis, pneumonitis, colitis, esophagitis and encephalitis. 
Probable CMV disease was defined as exhibiting clinical signs and 
symptoms without biopsy. Symptoms were not attributed to CMV if 
another cause was suspected or there was concomitant rejection.
The research was approved by the Research Ethics Committee of the 
Faculty of Medical Sciences, University of Campinas (São Paulo, Brazil).
PBl nucleic acid extraction
Extraction of nucleic acid from PBLs was accomplished using the 
method by Schmidt et al (17) with adaptations for CMV-DNA extrac-
tion. One millilitre of 6% dextran solution was added to every 4 mL of 
PBLs to separate them by gravity sedimentation. Contaminating eryth-
rocytes were lysed using a solution containing NH4Cl (8 g/L) and 
NH4HCO3 (0.8 g/L) at 4°C. After alkaline lysis with NaOH and heat 
denaturing for 30 min at 100°C, samples were adjusted to pH 8.4 by 
adding 1 M Tris-HCl.
Serum nucleic acid extraction
Serum nucleic acid extraction was accomplished using the method 
described by Di Pentima et al (18), with some modifications.
Aliquots of 100 µL of serum were incubated with 200 µL of 2× buf-
fer at 100°C, for 5 min (composition: 0.1 M KCl; 0.02 M Tris-HCl, 
pH 8.3; 0.005 M MgCl2; 0.2 mg/mL gelatin; 0.9% Nonidet P-40; 0.9% 
Tween 20). After 10 min centrifugation at 14.000 rpm, the super-
natant was transferred to another tube and stored at –20°C until PCR 
amplification.
CMV nested PCr
Avoiding contamination: Procedures to avoid contamination were 
strictly followed: DNA extraction was conducted in a positive pressure 
laminar flow hood; reaction mix preparation and the DNA samples 
extracted were aliquoted in different cabins; and the product electro-
phoresis was conducted in a separate room equipped with separate 
pipettes, aerosol resistant tips and reagents. In addition, negative 
(water) and positive (strain AD169 aliquot) controls were included in 
each PCR experiment.
Sensitivity
To determine the sensitivity of the nested PCR, a DNA fragment of 
620 base pairs (bp) containing the immediate-early gene region 1, 
the same fragment amplified by the primers MIE-4 and MIE-5 and 
IE-1 and IE-2, was created from the AD169 strain and the primer 
set MIE′ (MIE-1) 5′–GGTGCTCACGCACATTGATC–3′ and 
MIE-5 5′–CAGCACCATCCTCCTCTTCCTCTGG–3′. After 
cloning into a pGEM T easy vector (Promega, USA), the fragment 
was propagated in chemically competent Escherichia coli dH5α cells. 
Plasmid DNA was purified from transformed cells using the Concert 
Rapid Plasmid Purification System (Life Technologies, USA) and 
quantified by spectrophotometric analysis at 260 nm, on the basis of 
plasmid size and the corresponding DNA mass. Plasmid dilutions, 
representing 104 to 100 copies of DNA, were used as a template. 
Similarly, the sensitivity of nested sPCR was determined using serum 
samples from CMV-seronegative patients.
nested l-PCr
To verify the integrity and quality of the DNA extracted, all samples 
were initially amplified using the primer set PCO3+ 
5′–CCTCTGACACAACTGTGTTCACTAGC–3′ and PCO4+ 
5′–TCACCACCAACTTCATCCACGTTCACC–3′ (19,20), 
according to the same reaction conditions of reagent concentrations in 
the first PCR reaction for detection of CMV-DNA by nested PCR, as 
described below. The samples were amplified for 30 to 35 cycles of 
DNA denaturation at 94°C for 45 s, followed by primer annealing at 
55°C for 45 s and DNA extension at 72°C for 60 s. The initial cycle of 
PCR denaturation and final extension were conducted at 94°C for 
5 min and at 72°C for 7 min, respectively. The amplification product 
consisted of a 110 bp sequence.
The outer primer set MIE-4 5′–CCAAGCGGCCTCTG 
ATAACCAAGCC–3′ and MIE-5 5′–CAGCACCATCCTCCTC 
TTCCTCTGG–3′ (21,22), amplifying a 435 bp sequence; and the 
inner primer set IE-1 5′–CCACCCGTGGTGCCAGCTCC–3′ and 
IE-2 5′–CCCGCTCCTCCTGAGCACCC–3′ (22-24), amplifying a 
159 bp sequence, were used for CMV nested PCR. All four primer 
sequences are complementary to the immediate-early gene region 1. 
The reaction mixture consisted of: 0.8 µL of DNA, 2 µL of buffer 10× 
(composition: 500 mM KCl, 200 mM Tris-HCl, pH=8.4), 1.5 mM 
MgCl2, 2 µL of each deoxynucleotide triphosphate (dATP, dCTP, 
dTTP and dGTP), 1.5 mM, 2 µM of each primer and 0.5 U Thermus 
aquaticus (Taq) DNA polymerase recombinant (Life Technologies, 
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USA) to a final volume of 20 µL. The tubes were covered with mineral 
oil to prevent evaporation, and PCR was conducted in an automated 
thermal cycler (RobocyclerTM 40, Stratagene, USA). The amplifica-
tion reactions were run for 30 to 35 cycles of DNA denaturation at 
94°C for 60 s, followed by primer annealing at 55°C for 60 s and DNA 
extension at 72°C for 90 s. The initial cycle of PCR denaturation and 
final extension were performed at 94°C for 5 min and at 72°C for 
7 min, respectively.
In the nested PCR step (second reaction), 0.6 µL of the product 
from the first amplification was added to a new reaction mixture with 
2 µM of each inner primer (IE-1 and IE-2) and amplified with 30 to 
35 cycles, changing to 94°C for 40 s, followed by primer annealing at 
57°C for 40 s and DNA extension at 72°C for 90 s.
The nested PCR products were electrophoresed on a 2% agarose 
gel containing ethidium bromide, and the results were photographed 
using a Kodak Gel Logic 100 Imaging System over ultraviolet light, 
after staining with ethidium bromide (0.1 µg/mL).
nested sPCr
To verify the presence of inhibitors of Taq DNA polymerase by 
nested sPCR, a recombinant molecule of 377 bp (internal control) 
was constructed, in accordance with Zipeto et al (25), with the 
primer set 1 5′–CAAGCGGCCTCTGATAACCAAGCCGGTTAT
TGTCTCATGAGCGG–3′ and 2 5′–CAGCACCATCCTCCTCTT
CCTCTGGTGCTCTGATGCCGCATAGTT–3′, containing the 
complementary regions of the MIE-4 and MIE-5 primers and 0.025 µg 
of the plasmid PGEM-4Z (Promega, USA).
The samples containing DNA (5 µL of alkaline lysates) were then 
initially amplified in the presence of an aliquot (1 µL) of the molecule 
synthesized using the same reagent concentrations under amplification 
conditions of the first L-PCR reaction but in a final volume of 50 µL.
Only the positive internal control serum samples were submitted to 
nested PCR for CMV DNA detection, following the same parameters 
of the reaction mixture and L-PCR amplification, with a final volume 
of 50 µL and 5 µL of alkaline lysates.
Diagnostic criteria
Active CMV infection was defined based on the following criteria: 
two or more consecutive positive L-PCR and sPCR results. For the 
diagnosis of CMV disease, the active infection had to be accompanied 
by clinical symptoms and histopathological identification of CMV. 
Recurrence of CMV infection was defined as active CMV infection 
occurring after negative L-PCR and sPCR following treatment of the 
initial episode of infection. Late active CMV infections and diseases 
were defined as those occurring more than 100 days after transplant.
Statistical analysis
The laboratory results were compared with the presence/absence of 
CMV-related disease by calculating the following four statistical par-
ameters: sensitivity; specificity; positive predictive value; and negative 
predictive value (26). The Fisher’s exact test was used for comparison 
between groups. The degree of concordance between the methods was 
determined using the kappa coefficient (results were interpreted 
according to the criteria established by Landis and Koch [27]).
rESulTS
The target CMV DNA was detected at the level of 102 by single PCR 
and 101, equivalent to 10 copies of target DNA, by nested PCR. 
Although 21 of 37 patients (57%) developed active CMV infection, 
all of these were positive according to L-PCR (P=0.0003) (Figure 1). 
Only 10 PCR-positive serum patients (Figure 2) had active CMV 
infection (10 of 37 [27%]; P=0.01). Serum samples that showed no 
amplification of the internal control (377 bp fragment), due to pos-
sible presence of PCR inhibitors, were extracted again, and then 
evaluated for the presence of CMV DNA (Figure 3). Discordant 
results were observed in 11 patients who were L-PCR-positive but 
sPCR-negative for active CMV infection, five of whom developed 
clinical symptoms of CMV. The observed kappa coefficient of agree-
ment for both assays was 0.44 (moderate agreement). Sixteen of 
37 patients (43%) did not develop active CMV infection; however, 
two of these developed clinical symptoms of probable CMV disease 
and one presented later confirmatory biopsy for CMV disease. 
Clinical symptoms were observed in 14 patients, 12 of whom were 
diagnosed with active infection by L-PCR (P=0.007) and seven by 
sPCR (P=0.02) (Table 1). Absence of clinical symptoms was observed 
in nine patients diagnosed with active CMV infection by L-PCR, and 
three patients diagnosed by sPCR (kappa coefficient 0.57, moderate 
agreement). Of the 14 symptomatic patients, two CMV-seronegative 
patients who received seropositive kidneys developed primary infec-
tion. Analyzing the two methods for the diagnosis of active infection, 
a higher sensitivity and a higher negative predictive value for was 
observed L-PCR (L-PCR 100% versus sPCR 62%), and a higher speci-
ficity and positive predictive value was observed for sPCR (sPCR 81% 
versus L-PCR 50% and 72%). The values of L-PCR- or sPCR-positive 
tests to predict CMV disease were 57% and 70%, respectively, and the 
value of negative tests to predict that CMV disease would not develop 
Figure 1) Amplicon seen in reaction amplification through peripheral 
blood polymerase chain reaction (‘L-PCR’); M: 100 bp DNA ladder; C+: 
Positive control, lanes 1, 4, 5, 8 and 14: positive samples; 2, 3, 6, 7, 9–13, 
15–17: negative samples; 18: water (blank) 
Figure 2) Amplicon seen in reaction amplification by serum polymerase 
chain reaction (‘s-PCR’). M: 100 bp DNA ladder; C+: Positive control 
(strain AD169); Lanes 1–14, 16–19: negative samples; 15: positive sam-
ples; 20: water (blank)
Figure 3) Internal control (377 base pair amplicon) to verify the presence 
of inhibitors in serum samples. M: 100 base pair DNA ladder; C+: Positive 
control, lanes 1–14 (above) and 1–13 (below): positive internal control 
serum samples, absence of inhibitors; 14: water (blank)
   M    C+     1     2      3      4      5     6      7      8     9     10     11   12   13     14   15    16    17    18
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was 88% for L-PCR and 74% for sPCR. The comparative analysis 
between the first positive results for the presence of active CMV infec-
tion and the onset of symptoms showed that the L-PCR test preceded 
the onset of clinical symptoms by a mean of 19 days in eight patients. 
In two patients, the sPCR test preceded the L-PCR test by a mean of 
seven days for detection of symptomatic CMV infection.
DISCuSSIOn
The search for establishing a better correlation between the detection 
of CMV viral genome and disease development has contributed to the 
improvement of amplification techniques (28). Questions related to 
the type of sample that better reflects active infection have also motiv-
ated scientific research (29).
Methodologies based on quantification of viral load, such as real-
time PCR, have advantages including shorter time to results and lower 
possibility of contamination (5). However, these methods have ele-
vated costs (4) – both the devices and the reagents necessary for their 
application (6). Regarding cost analysis, the nested PCR presents 
advantages when compared with real-time PCR; however, the high 
sensitivity associated with the method used to detect CMV DNA from 
leukocytes limits the clinical application of the technique because 
viral DNA may be detected in seropositive patients in the absence of 
disease (30).
The detection of CMV DNA from plasma and serum of immuno-
compromised patients suggests the existence of an alternative mech-
anism for virus dissemination within the host; plasma and serum, 
therefore, may be considered sources of material for detection of infec-
tion disseminated by CMV (31). Although there is no a consensus in 
the literature concerning the presence of CMV DNA in these clinical 
samples, they have been widely used in viral diagnosis (32,33).
Analyzing the two methods in relation to the detection of active 
infection and probable CMV disease, we verified that the sensitivity 
and specificity values, as well as positive predictive and negative pre-
dictive values corroborate the literature data. High sensitivity in the 
detection of CMV DNA and low specificity for disease diagnosis are 
associated with PCR in leukocytes (34,35), justifying the 100% sensi-
tivity and negative predictive value obtained in the diagnosis of active 
infection, but specificity of 50%, because positive results were observed 
in eight of 16 patients without active infection. sPCR was less sensi-
tive compared with L-PCR for the diagnosis of active infection, with a 
62% sensitivity and negative predictive value; however, it demon-
strated greater specificity, with specificity and positive predictive value 
of 81%. The higher sensitivity of PCR from leukocytes, compared with 
the use of serum in the present study, agrees with results reported in 
the literature (7,8,36).
Isolated positive results observed in the present study were detected 
by L-PCR and sPCR, which did not characterize active infection; 
however, they were not considered false positives because the neces-
sary conditions to avoid contamination of samples during amplifica-
tion reactions were stringently observed. The detection of CMV DNA 
by PCR in the plasma of patients who have undergone bone marrow 
transplant (7) confirms the possibility of virus replication in other sites 
than polymorphonuclear cells and, perhaps, endothelial cells, justify-
ing some isolated positive results observed in serum samples (8,37).
Sixteen patients did not show active infection. Of these, 14 remained 
asymptomatic during the entire follow-up period; however, two of 
these 16 patients developed symptoms suggestive of infection by CMV. 
One patient (patient 25) was gastric biopsy positive for cytomegalic 
disease, while the other (patient 37) had a gastric biopsy suggestive of 
herpesvirus. However, it was not confirmed whether CMV was the 
pathogenic cause of infection. The two patients were treated with 
gancyclovir. These results are in accordance with the literature. Zipeto 
et al (31) observed negativity in DNA samples extracted from leuko-
cytes of a patient who developed CMV disease, inferring that infec-
tions located in highly vascularized sites contribute to the absence of 
infection in PBLs.
For the diagnosis of probable disease, a higher sensitivity of L-PCR 
(86% versus 50% sPCR) and a higher negative predictive value (88% 
versus 74% sPCR) were also observed; however, a lower specificity 
(61% versus 87% sPCR) and positive predictive value (57% versus 
70% sPCR) were also observed. Abecassis et al (38,39) found similar 
results and affirmed that qualitative PCR has a low positive predictive 
value for the development of disease. However, presenting results simi-
lar to ours, the detection of CMV DNA in plasma was considered by 
TAble 1
Chronology of cytomegalovirus infection detected in 
peripheral blood leukocytes (Pbl) – nested polymerase 
chain reaction (PCR) and serum PCR and clinical 
manifestations
Patient Clinical manifestations
Day post-transplant 
Pbl – nested 
PCR (+) Serum PCR (+)
1 Prolonged fever, liver enzyme 
alterations
8, 20, 27 8, 13, 20, 27, 
34, 48
2 Fever, leukopenia 12, 21, 27, 33 5, 21, 27, 33, 
47
3 Thrombocytopenia, liver enzyme 
alterations
7, 12, 19, 26 –
4 Renal function alteration,  
thrombocytopenia
18, 25, 38, 52, 
59, 66, 73, 80
11, 18, 25, 38, 
73, 126
5 Fever, myalgia, liver enzyme 
alterations, leukopenia
42, 52, 58, 70, 
105
52, 58, 105
7 Fever, liver enzyme alterations, 
leukopenia
36, 50 50, 57
8 – 41, 48 48, 55
9 – 42, 49, 65 29, 42, 49, 65, 
77
10 Liver dysfunction, renal function 
alteration
4, 17, 26 26
12 Fever, leukopenia 39, 46, 53 –
14 Pancytopenia 12, 19, 26 19
16 – 68, 80, 87, 94, 
110
0, 68, 80, 87, 
110
17 Leukopenia 48, 56, 62, 77, 
84
48, 56, 62, 77, 
84
21 – 32, 46, 61, 75, 
119
–
22 Arthralgia 29, 47, 62, 77, 
89, 105, 110, 
117
62, 77
24 – 42, 63, 69 –
25 Chronic mucositis in esophagus, 
stomach and duodenum  
(gastric biopsy positive for  
cytomegalic disease: gastrodu-
odenitis and acute esophagitis 
by cytomegalovirus) 
– –
27 – 29, 42 8, 42
28 – 0, 21, 35 –
30 – 48, 69, 84 –
33 Hepatosplenomegaly, liver  
insufficiency, hepatic  
encephalopathy
32, 40, 45, 47 –
35 – 18, 41 –
37 Oral herpetic mucositis, febrile 
neutropenia, acute esophagitis 
(gastric biopsy: acute esophagitis 
with alterations suggestive of 
herpesvirus) 
– –
Patients 6, 11, 13, 15, 18, 19, 20, 23, 26, 29, 31, 32, 34 and 36 had no active 
infection or clinical symptoms of cytomegalovirus
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Spector et al (9) as the most convincing risk sign of development of 
CMV disease. L-PCR detected active infection by CMV in nine of 
16 patients who did not present clinical manifestations of probable 
CMV disease. These results corroborate those in the literature, because 
viral replication with high levels of viral charge is observed in patients 
who are asymptomatic for CMV (37 patients), which justifies the posi-
tive results observed that characterize active infection in nine asymp-
tomatic patients. Five patients were diagnosed with active infection 
only by L-PCR (patients 3, 10, 12, 17 and 36). Therefore, sPCR pre-
sented a sensitivity of only 50% when detecting active infection in 
only seven of 14 patients who presented clinical manifestations. 
According to the literature, PCR application in plasma is useful in 
situations of absolute neutropenia (7,34). We observed that, of 
31 samples in which L-PCR application was not possible (not only due 
to neutropenia), four of 31 (13%) presented detectable CMV DNA in 
the serum, confirming the usefulness of this technique situations in 
which PCR of leukocyte DNA cannot be performed (40). The use of a 
recombinant DNA molecule as an internal control enabled the detec-
tion of the inhibitor effect in the sPCR in 13 of 101 samples of serum 
tested, which is equivalent to 13%. 
Administration of antiviral therapy before CMV disease manifesta-
tion requires rapid and cost-effective methods of detection (41). L-PCR 
preceded clinical symptoms by a mean of 19 days in 67% (eight of 
12 patients) of cases in which active infection was detected. The speed of 
detecting CMV DNA in relation to the appearance of clinical manifesta-
tions has been demonstrated when PCR is applied to leukocytes (12,42).
COnCluSIOn
L-PCR and sPCR were considered as complementary methods for the 
diagnosis and management of symptomatic CMV infection. The inter-
nal control used in sPCR allowed a greater reliability for testing and 
excluding false-negative results. 
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